Greyverse

In this case study, a 25-year-old female with premature hair graying achieved over 90% conversion of gray hair to black hair after 5 months of treatment with a topical peptide solution and hair supplements.

In this study, application of Revgrey® hair serum was found to be safe and may offer some benefit in treating premature greying of hair, with slightly to moderately increased hair recovery observed in a small group of patients after 12 weeks.

The combination of a plant extract and a peptide can increase hair pigmentation and may reverse greying.

This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.

This narrative review analyzed the literature on premature hair graying, identifying potential contributors such as nutrient deficiencies, oxidative and emotional stress, smoking, genetic factors, autoimmune diseases, and medication side effects, but reported no effective treatment to reverse it, underscoring the necessity for further research.

This article discusses the challenges in understanding and treating premature graying of hair and calls for more extensive research, reporting no new findings.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

This article reviews the clinical complications and increased mortality risks associated with Cushing's syndrome but does not present new clinical data; it emphasizes the need for prompt treatment to mitigate these risks.

This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.

This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.

This study found that using a low-level laser comb led to hair regrowth in a mouse model of alopecia areata, while sham-treated mice showed no hair regrowth.

This study found that in vivo, a novel microneedle system for valproic acid delivery may improve hair regrowth efficacy by upregulating hair follicle development pathways more effectively than topical application.

This genome-wide association study identified 20 genetic signals at 15 risk loci related to severe acne, revealing new insights into its genetic predisposition, particularly affecting skin structure and maintenance.

This review discusses the involvement of type I interferons in skin autoimmune and inflammatory diseases but reports no new clinical results.

This study reports that riboflavin may increase enzymatic activity in a GCDH-deficient patient with specific mutations, but doesn't fully normalize urinary organic acid levels.

This article reviews the roles of lesser-known secreted phospholipase A2 isoforms in various biological processes, such as immune suppression, metabolic regulation, epidermal hyperplasia, and male reproduction, without reporting new clinical findings.

This review discusses the role of acyl-CoA binding protein (ACBP) in the epidermal barrier, noting that its disruption in mice is linked to skin and fur abnormalities; it reports no new clinical results.

This study reported that oral simvastatin/ezetimibe therapy was ineffective for treating alopecia areata, with 67% of participants experiencing no hair regrowth. Additionally, 24% of patients experienced adverse effects, including myalgia, highlighting the need to weigh potential risks against questionable benefits.

This review discusses the mechanisms underlying immune tolerance failure in alopecia areata and highlights potential therapeutic avenues for restoring hair growth and achieving sustained remission, but reports no new clinical results.

This study reports a unique case of common variable immunodeficiency with autoimmunity linked to a heterozygous S250C variant in the autoimmune regulator gene, suggesting a potential molecular basis for this combination.